{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:28:14Z","timestamp":1789421294175,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40120-025-00839-2","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:28:38Z","timestamp":1761665318000},"page":"2695-2721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Patient\u2013Doctor Communication in Migraine: Results from the OVERCOME (Japan) 2nd Study"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7430-2078","authenticated-orcid":false,"given":"Shiho","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6976-1081","authenticated-orcid":false,"given":"Ryotaro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3737-4754","authenticated-orcid":false,"given":"Daisuke","family":"Danno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2605-7200","authenticated-orcid":false,"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1823-8394","authenticated-orcid":false,"given":"Masayuki","family":"Hamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5014-2483","authenticated-orcid":false,"given":"Yoshinori","family":"Tanizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-2469","authenticated-orcid":false,"given":"Satoshi","family":"Osaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2252-6724","authenticated-orcid":false,"given":"Nao","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0227-8993","authenticated-orcid":false,"given":"Chie","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-1296","authenticated-orcid":false,"given":"Mika","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"839_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17:15\u201322.","journal-title":"Cephalalgia"},{"key":"839_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1526-4610.2004.04004.x","volume":"44","author":"T Takeshima","year":"2004","unstructured":"Takeshima T, Ishizaki K, Fukuhara Y, Ijiri T, Kusumi M, Wakutani Y, et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache. 2004;44:8\u201319.","journal-title":"Headache"},{"key":"839_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s10194-021-01243-5","volume":"22","author":"T Shimizu","year":"2021","unstructured":"Shimizu T, Sakai F, Miyake H, Sone T, Sato M, Tanabe S, et al. Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. J Headache Pain. 2021;22:29.","journal-title":"J Headache Pain"},{"key":"839_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-020-01180-9","volume":"21","author":"S Kikui","year":"2020","unstructured":"Kikui S, Chen Y, Todaka H, Asao K, Adachi K, Takeshima T. Burden of migraine among Japanese patients: a cross-sectional national health and wellness survey. J Headache Pain. 2020;21:110.","journal-title":"J Headache Pain"},{"key":"839_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-038987","volume":"10","author":"H Igarashi","year":"2020","unstructured":"Igarashi H, Ueda K, Jung S, Cai Z, Chen Y, Nakamura T. Social burden of people with the migraine diagnosis in Japan: evidence from a population-based cross-sectional survey. BMJ Open. 2020;10:e038987.","journal-title":"BMJ Open"},{"key":"839_CR6","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2021.1971179","volume":"37","author":"K Hirata","year":"2021","unstructured":"Hirata K, Ueda K, Komori M, Zagar AJ, Selzler KJ, Nelson AM, et al. Comprehensive population-based survey of migraine in Japan: results of the observational survey of the epidemiology, treatment, and care of migraine (OVERCOME [Japan)] study. Curr Med Res Opin. 2021;37:1945\u201355.","journal-title":"Curr Med Res Opin"},{"key":"839_CR7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40120-023-00569-3","volume":"13","author":"E Awaki","year":"2024","unstructured":"Awaki E, Takeshima T, Matsumori Y, Hirata K, Miyazaki N, Takemura R, et al. Impact of migraine on daily life: results of the observational survey of the epidemiology, treatment, and care of migraine (OVERCOME [Japan)] study. Neurol Ther. 2024;13:165\u201382.","journal-title":"Neurol Ther"},{"key":"839_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40120-021-00305-9","volume":"11","author":"Y Matsumori","year":"2022","unstructured":"Matsumori Y, Ueda K, Komori M, Zagar AJ, Kim Y, Jaffe DH, et al. Burden of migraine in Japan: results of the ObserVational survey of the epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan)] study. Neurol Ther. 2022;11:205\u201322.","journal-title":"Neurol Ther"},{"key":"839_CR9","unstructured":"Institute of Medical Studies. Headache practice guidelines 2021 [in Japanese]. 2021:512."},{"key":"839_CR10","unstructured":"Pharmaceuticals and Medical Devices Agency. List of approved drugs April 2004 to January 2024: Pharmaceuticals and Medical Devices Agency; 2024 [cited March 03, 2025]. Available from: https:\/\/www.pmda.go.jp\/files\/000272313.pdf."},{"key":"839_CR11","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/pm\/pnae050","volume":"25","author":"S Kikui","year":"2024","unstructured":"Kikui S, Daisuke D, Miyahara J, Sugiyama H, Ota K, Murakata K, et al. Effectiveness of fremanezumab treatment in patients with migraine headache. Pain Med. 2024;25:664\u201370.","journal-title":"Pain Med"},{"key":"839_CR12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12883-023-03449-3","volume":"23","author":"S Ohtani","year":"2023","unstructured":"Ohtani S, Watanabe N, Ihara K, Takahashi N, Miyazaki N, Ishizuchi K, et al. Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study. BMC Neurol. 2023;23:404.","journal-title":"BMC Neurol"},{"key":"839_CR13","doi-asserted-by":"publisher","first-page":"1220285","DOI":"10.3389\/fneur.2023.1220285","volume":"14","author":"S Suzuki","year":"2023","unstructured":"Suzuki S, Suzuki K, Shiina T, Haruyama Y, Hirata K. Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan. Front Neurol. 2023;14:1220285.","journal-title":"Front Neurol"},{"key":"839_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26568","volume":"10","author":"K Suzuki","year":"2024","unstructured":"Suzuki K, Suzuki S, Shiina T, Haruyama Y, Kobayashi S, Shioda M, et al. Real-world effectiveness of erenumab in Japanese patients with migraine. Heliyon. 2024;10:e26568.","journal-title":"Heliyon"},{"key":"839_CR15","doi-asserted-by":"crossref","unstructured":"Ihara K, Takahashi N, Ohtani S, Watanabe N, Ishizuchi K, Takemura R, et al. Real-world efficacy of erenumab on migraine-associated symptoms and patient-reported satisfaction levels: a retrospective study in Japan. Intern Med. 2025;64:825\u201331.","DOI":"10.2169\/internalmedicine.4037-24"},{"key":"839_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12883-022-03041-1","volume":"22","author":"T Takizawa","year":"2022","unstructured":"Takizawa T, Ohtani S, Watanabe N, Miyazaki N, Ishizuchi K, Sekiguchi K, et al. Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol. 2022;22:512.","journal-title":"BMC Neurol"},{"key":"839_CR17","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s00415-023-11788-x","volume":"270","author":"K Suzuki","year":"2023","unstructured":"Suzuki K, Suzuki S, Shiina T, Haruyama Y, Fujita H, Funakoshi K, et al. Could efficacy at 1 week after galcanezumab administration for patients with migraine predict responders at 3 months? A real world study. J Neurol. 2023;270:4377\u201384.","journal-title":"J Neurol"},{"key":"839_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12883-023-03521-y","volume":"24","author":"M Shibata","year":"2024","unstructured":"Shibata M, Fujita K, Hoshino E, Minami K, Koizumi K, Okada S, et al. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers. BMC Neurol. 2024;24:32.","journal-title":"BMC Neurol"},{"key":"839_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231177649","volume":"43","author":"K Suzuki","year":"2023","unstructured":"Suzuki K, Suzuki S, Shiina T, Tatsumoto M, Fujita H, Haruyama Y, et al. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: a 12-month, single-center, observational real-world study in Japan. Cephalalgia. 2023;43:3331024231177649.","journal-title":"Cephalalgia"},{"key":"839_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.120811","volume":"453","author":"K Ihara","year":"2023","unstructured":"Ihara K, Ohtani S, Watanabe N, Takahashi N, Miyazaki N, Takemura R, et al. Switching between anti-calcitonin gene-related peptide monoclonal antibodies: a comparison of monthly and quarterly dosing. J Neurol Sci. 2023;453:120811.","journal-title":"J Neurol Sci"},{"key":"839_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-023-01556-7","volume":"24","author":"K Ihara","year":"2023","unstructured":"Ihara K, Ohtani S, Watanabe N, Takahashi N, Miyazaki N, Ishizuchi K, et al. Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study. J Headache Pain. 2023;24:23.","journal-title":"J Headache Pain"},{"key":"839_CR22","volume":"15","author":"M Katsuki","year":"2023","unstructured":"Katsuki M, Kashiwagi K, Kawamura S, Koh A. Monoclonal antibodies against the calcitonin gene-related peptide and its receptor in Japanese adolescents with migraines. Cureus. 2023;15:e33689.","journal-title":"Cureus"},{"key":"839_CR23","doi-asserted-by":"publisher","first-page":"333102424125869","DOI":"10.1177\/03331024241258695","volume":"44","author":"R Ishii","year":"2024","unstructured":"Ishii R, Ishizuchi K, Watanabe N, Fukazawa R, Trivedi M, Nakahara J, et al. Efficacy and tolerability of 100 mg of lasmiditan for migraine: a multi-center, prospective observational real-world study in Japan. Cephalalgia. 2024;44:3331024241258695.","journal-title":"Cephalalgia"},{"key":"839_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s10194-024-01745-y","volume":"25","author":"M Komori","year":"2024","unstructured":"Komori M, Ozeki A, Tanji Y, Kamiki E, Krege JH, Li LQ, et al. Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial. J Headache Pain. 2024;25:43.","journal-title":"J Headache Pain"},{"key":"839_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (HIS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (HIS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211.","journal-title":"Cephalalgia"},{"key":"839_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40120-024-00690-x","volume":"14","author":"D Danno","year":"2025","unstructured":"Danno D, Suzuki S, Takizawa T, Ishii R, Hamakawa M, Tanizawa Y, et al. The impact of migraine on the whole life course of patients: results from the OVERCOME (Japan) 2nd study. Neurol Ther. 2025;14:335\u201356.","journal-title":"Neurol Ther"},{"key":"839_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-077686","volume":"14","author":"H Igarashi","year":"2024","unstructured":"Igarashi H, Sano H, Kondo H, Shibasaki Y, Koga N. Characteristics of patients who seek medical attention for headache and those who do not: cross-sectional survey and linked medical claims data analysis in Japan. BMJ Open. 2024;14:e077686.","journal-title":"BMJ Open"},{"key":"839_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2023.1271438","volume":"4","author":"Y Karasawa","year":"2023","unstructured":"Karasawa Y, Yamaguchi K, Nakano S, Nozawa K, Iseki M. Barriers to healthcare access in patients with chronic pain or potential migraine in Japan: a cross-sectional internet survey. Front Pain Res (Lausanne). 2023;4:1271438.","journal-title":"Front Pain Res (Lausanne)"},{"key":"839_CR29","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1185\/03007990802122388","volume":"24","author":"SR Hahn","year":"2008","unstructured":"Hahn SR, Lipton RB, Sheftell FD, Cady RK, Eagan CA, Simons SE, et al. Healthcare provider-patient communication and migraine assessment: results of the American Migraine Communication Study, phase II. Curr Med Res Opin. 2008;24:1711\u20138.","journal-title":"Curr Med Res Opin"},{"key":"839_CR30","first-page":"2105","volume":"92","author":"M Hasegawa","year":"2004","unstructured":"Hasegawa M, Igarashi H. Actual patient satisfaction with migraine treatment (in Japanese). Diagn Treat. 2004;92:2105\u201312.","journal-title":"Diagn Treat"},{"key":"839_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s41649-021-00201-2","volume":"14","author":"A Asai","year":"2022","unstructured":"Asai A, Okita T, Bito S. Discussions on present Japanese psychocultural-social tendencies as obstacles to clinical shared decision-making in Japan. Asian Bioeth Rev. 2022;14:133\u201350.","journal-title":"Asian Bioeth Rev"},{"key":"839_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.pec.2006.11.004","volume":"65","author":"S Okamoto","year":"2007","unstructured":"Okamoto S. Transformations in doctor-patient communication in Japan: the role of cultural factors. Patient Educ Couns. 2007;65:153\u20135.","journal-title":"Patient Educ Couns"},{"key":"839_CR33","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/head.13314","volume":"58","author":"DC Buse","year":"2018","unstructured":"Buse DC, Gillard P, Arctander K, Kuang AW, Lipton RB. Assessing physician-patient dialogues about chronic migraine during routine office visits. Headache. 2018;58:993\u20131006.","journal-title":"Headache"},{"issue":"Suppl 2","key":"839_CR34","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1007\/s10072-007-0765-5","volume":"28","author":"GC Manzoni","year":"2007","unstructured":"Manzoni GC, Torelli P. The patient-physician relationship in the approach to therapeutic management. Neurol Sci. 2007;28(Suppl 2):S130\u20133.","journal-title":"Neurol Sci"},{"key":"839_CR35","unstructured":"Results of 2020 Population Census: Statistics Bureau, Ministry of Internal Affairs and Communications; 2023 [cited March 19, 2023]. Available from: https:\/\/www.stat.go.jp\/data\/kokusei\/2020\/kekka.html."},{"key":"839_CR36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1526-4610.2003.03069.x","volume":"43","author":"M Iigaya","year":"2003","unstructured":"Iigaya M, Sakai F, Kolodner KB, Lipton RB, Stewart WF. Reliability and validity of the Japanese Migraine Disability Assessment (MIDAS) questionnaire. Headache. 2003;43:343\u201352.","journal-title":"Headache"},{"key":"839_CR37","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12:963\u201374.","journal-title":"Qual Life Res"},{"key":"839_CR38","volume":"68","author":"D Buse","year":"2007","unstructured":"Buse D, Bigal MB, Rupnow M, Reed M, Serrano D, Lipton R. Development and validation of the Migraine Interictal Burden Scale (MIBS): a self-administered instrument for measuring the burden of migraine between attacks. Neurology. 2007;68:A89.","journal-title":"Neurology"},{"key":"839_CR39","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0025-6196(11)60561-2","volume":"84","author":"DC Buse","year":"2009","unstructured":"Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84:422\u201335.","journal-title":"Mayo Clin Proc"},{"key":"839_CR40","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/head.13028","volume":"57","author":"RB Lipton","year":"2017","unstructured":"Lipton RB, Buse DC, Adams AM, Varon SF, Fanning KM, Reed ML. Family impact of migraine: development of the impact of migraine on partners and adolescent children (IMPAC) scale. Headache. 2017;57:570\u201385.","journal-title":"Headache"},{"key":"839_CR41","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40122-024-00589-3","volume":"13","author":"S Evers","year":"2024","unstructured":"Evers S, Dell\u2019Agnello G, Novick D, Gonderten HS, Panni T, Pascual J. Acute treatment patterns, migraine burden, and healthcare resource use in people with migraine: results from the OVERCOME (EU) observational study. Pain Ther. 2024;13:589\u2013607.","journal-title":"Pain Ther"},{"key":"839_CR42","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/head.14259","volume":"62","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, Nicholson RA, Reed ML, Araujo AB, Jaffe DH, Faries DE, et al. Diagnosis, consultation, treatment, and impact of migraine in the US: results of the OVERCOME (US) study. Headache. 2022;62:122\u201340.","journal-title":"Headache"},{"issue":"Suppl 2","key":"839_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-2982.2008.01684.x","volume":"28","author":"M Lanteri-Minet","year":"2008","unstructured":"Lanteri-Minet M. The role of general practitioners in migraine management. Cephalalgia. 2008;28(Suppl 2):1\u20138.","journal-title":"Cephalalgia"},{"key":"839_CR44","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-023-01652-8","volume":"24","author":"G Vaghi","year":"2023","unstructured":"Vaghi G, De Icco R, Tassorelli C, Goadsby PJ, Vicente-Herrero T, de la Torre ER. Who cares about migraine? Pathways and hurdles in the European region\u2014access to care III. J Headache Pain. 2023;24:120.","journal-title":"J Headache Pain"},{"key":"839_CR45","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1080\/07853890.2021.1995626","volume":"53","author":"VT Martin","year":"2021","unstructured":"Martin VT, Feoktistov A, Solomon GD. A rational approach to migraine diagnosis and management in primary care. Ann Med. 2021;53:1979\u201390.","journal-title":"Ann Med"},{"key":"839_CR46","unstructured":"Beithon J, Gallenberg M, Johnson K, K P, K J, Liebow M, et al. Diagnosis and treatment of headache: health care guideline. Bloomington: Institute for Clinical Systems Improvement; 2013 [December 19, 2024]. Available from: https:\/\/www.icsi.org\/guidelines__more\/catalog_guidelines_and_more\/catalog_guidelines\/catalog_neurological_guidelines\/headache\/."},{"key":"839_CR47","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/papr.12243","volume":"15","author":"C Dougherty","year":"2015","unstructured":"Dougherty C, Silberstein SD. Providing care for patients with chronic migraine: diagnosis, treatment, and management. Pain Pract. 2015;15:688\u201392.","journal-title":"Pain Pract"},{"key":"839_CR48","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17:501\u201314.","journal-title":"Nat Rev Neurol"},{"key":"839_CR49","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1526-4610.2010.01778.x","volume":"51","author":"G Viticchi","year":"2011","unstructured":"Viticchi G, Silvestrini M, Falsetti L, Lanciotti C, Cerqua R, Luzzi S, et al. Time delay from onset to diagnosis of migraine. Headache. 2011;51:232\u20136.","journal-title":"Headache"},{"key":"839_CR50","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache S. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021\u201339.","journal-title":"Headache"},{"issue":"Suppl 2","key":"839_CR51","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/head.12505_2","volume":"5","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;5(Suppl 2):103\u201322 (quiz 23\u20136).","journal-title":"Headache"},{"key":"839_CR52","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1046\/j.1468-2982.2000.00082.x","volume":"20","author":"GM Davies","year":"2000","unstructured":"Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia. 2000;20:554\u201360.","journal-title":"Cephalalgia"},{"key":"839_CR53","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.998","volume":"98","author":"H Glassner","year":"2022","unstructured":"Glassner H, Klepper J, Cirillo J, Kim E, Lipton R. Patient satisfaction is associated with positive communications with health care professionals: interim results from a survey of an online migraine community (P5-2.004). Neurology. 2022;98:998.","journal-title":"Neurology"},{"issue":"Suppl 2","key":"839_CR54","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1017\/S0317167100001876","volume":"29","author":"J Edmeads","year":"2002","unstructured":"Edmeads J. Communication issues in migraine diagnosis. Can J Neurol Sci. 2002;29(Suppl 2):S8-10.","journal-title":"Can J Neurol Sci"},{"issue":"3","key":"839_CR55","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s11916-008-0040-3","volume":"12","author":"DC Buse","year":"2008","unstructured":"Buse DC, Lipton RB. Facilitating communication with patients for improved migraine outcomes. Curr Pain Headache Rep. 2008;12(3):230\u20136.","journal-title":"Curr Pain Headache Rep"},{"key":"839_CR56","first-page":"893","volume":"3","author":"M Patwardhan","year":"2007","unstructured":"Patwardhan M, Coeytaux RR, Deshmukh R, Samsa G. What is the impact of physician communication and patient understanding in the management of headache? Neuropsychiatr Dis Treat. 2007;3:893\u20137.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"839_CR57","first-page":"e175","volume":"8","author":"Y Yumiya","year":"2024","unstructured":"Yumiya Y, Goto A, Konta T. Association between health literacy and understanding of doctors\u2019 explanations: the Yamagata study. Health Lit Res Pract. 2024;8:e175\u201383.","journal-title":"Health Lit Res Pract"},{"key":"839_CR58","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12905-015-0203-4","volume":"15","author":"JY Siu","year":"2015","unstructured":"Siu JY. Communicating under medical patriarchy: gendered doctor-patient communication between female patients with overactive bladder and male urologists in Hong Kong. BMC Womens Health. 2015;15:44.","journal-title":"BMC Womens Health"},{"key":"839_CR59","doi-asserted-by":"crossref","unstructured":"Choudhury A, Elkefi S, Asan O. Impact of gender on doctor-patient communication and emotion: exploratory analysis. In: 2020 IEEE International Symposium on Systems Engineering (ISSE); Vienna, 2020, p. 1\u201310.","DOI":"10.1109\/ISSE49799.2020.9272228"},{"key":"839_CR60","doi-asserted-by":"publisher","DOI":"10.4103\/JNSM.JNSM_28_18","author":"G Alyahya","year":"2019","unstructured":"Alyahya G, Almohanna H, Alyahya A, Aldosari M, Mathkour L, Aldhibaib A, et al. Does physicians\u2019 gender have any influence on patients\u2019 choice of their treating physicians? J Nat Sci Med. 2019. https:\/\/doi.org\/10.4103\/JNSM.JNSM_28_18.","journal-title":"J Nat Sci Med"},{"key":"839_CR61","first-page":"147","volume":"102","author":"CS Weisman","year":"1987","unstructured":"Weisman CS. Communication between women and their health care providers: research findings and unanswered questions. Public Health Rep. 1987;102:147\u201351.","journal-title":"Public Health Rep"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00839-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:05:32Z","timestamp":1763424332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00839-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["839"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00839-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shiho Suzuki received speaker honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Ryotaro Ishii received consulting fees from Amgen K.K., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., and Otsuka Pharmaceutical Co., Ltd.; speaker honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., and Otsuka Pharmaceutical Co., Ltd. Daisuke Danno serves on the advisory boards of Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Lundbeck Japan K.K., Otsuka Pharmaceutical Co., Ltd., and Pfizer Japan Inc. and received speaker honoraria from Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Tsubasa Takizawa is a consultant\/adviser and\/or serves on an advisory board for Eli Lilly Japan K.K., Otsuka Pharmaceutical Co., Ltd., Amgen K.K., Pfizer Japan Inc., and Teijin Pharma Ltd. He received speaker honoraria from Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Amgen K.K., Eisai Co., Ltd., Sawai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Ltd., and Santen Pharmaceutical, a grant from Pfizer Japan Inc., and research funding from Eli Lilly Japan K.K. and Tsumura & Co., outside the submitted work. Masayuki Hamakawa is an employee of Social Survey Research Information Co., Ltd. Data collection and statistical analyses in this study were performed by Social Survey Research Information Co., Ltd. and sponsored by Eli Lilly Japan K.K. Yoshinori Tanizawa, Satoshi Osaga, Nao Sasaki, Chie Hashimoto, and Mika Komori are employees of Eli Lilly Japan K.K. and may own stock\/stock options of Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Medical Corporation TOUKEIKAI Kitamachi Clinic ethics committee approved this study (number BGQ09531) on April 19, 2023. This study was conducted in accordance with ethical principles originating from the Declaration of Helsinki, and that were consistent with Good Pharmacoepidemiology Practices. All survey respondents provided electronic informed consent and agreed to participate in the study. All data were anonymized before analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}